Immunotherapy Archives

News and Trends 13 May 2015

[UPDATE] Adaptimmune raised €156.7M in its IPO

Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company is focused on novel cancer immunotherapy products based on T-cell receptors. [UPDATE]: The company successfully raised the quantity expected. Adaptimmune is focused on the use of T-cell therapy to treat cancer. It aims to utilise the body’s own machinery, T […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 May 2015

Natural Killer therapies for Cancer: a Fast-Evolving field

Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors, that specifically regulate the activity of the immune system, are attracting the attention of several small startups and more than a few big Pharmas. The immune system includes a set of body defenses, that fight foreign forms. But external bodies aren’t […]

May 5, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 18 Apr 2015

Another Partnership between Immunocore and MedImmune against Skin Cancer

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca have just entered into a second effective collaboration for a potential skin cancer treatment. It concerns melanoma which is a form of skin cancer that accounts for less than five per cent of […]

April 18, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 24 Mar 2015

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new investment brings the total Series A to €14.2M to the biopharmaceutical company that is developing RNA-based immunotherapeutics for the treatment of […]

March 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 15 Oct 2014

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]

October 15, 2014 - 2 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of […]

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

[UPDATE] Adaptimmune raised €156.7M in its IPO

US-based Juno Therapeutics purchased a German biotech

Natural Killer therapies for Cancer: a Fast-Evolving field

Another Partnership between Immunocore and MedImmune against Skin Cancer

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

Affimed secures almost $30M in Financing to continue its clinical development

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!